These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34801033)

  • 21. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological significance of alternative splicing prognostic signatures for bladder cancer.
    Li X; Yang L; Huang W; Jia B; Lai Y
    Heliyon; 2022 Feb; 8(2):e08994. PubMed ID: 35243106
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Tao Y; Li X; Zhang Y; He L; Lu Q; Wang Y; Pan L; Wang Z; Feng C; Xie Y; Lai Z; Li T; Tang Z; Wang Q; Wang X
    Front Genet; 2022; 13():1057302. PubMed ID: 36568387
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA).
    Cao R; Yuan L; Ma B; Wang G; Tian Y
    Cancer Cell Int; 2020; 20():276. PubMed ID: 32607061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer.
    Wu Z; Feng Z; Wei H; Lin C; Chen K
    Front Med (Lausanne); 2023; 10():1193133. PubMed ID: 37780567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
    Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Natural Killer Cell-related Gene Signature for Improving the Prediction of Prognosis and Immunotherapy Response in Bladder Cancer.
    Ma X; Wei X; Yang G; Li S; Liu R
    Comb Chem High Throughput Screen; 2024; 27(8):1205-1221. PubMed ID: 37653625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of prognostic oncogene filaggrin (
    Chen L; Huang X; Xiong L; Chen W; An L; Wang H; Hong Y; Wang H
    Transl Androl Urol; 2022 Oct; 11(10):1419-1432. PubMed ID: 36386263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.
    Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
    Cancer Manag Res; 2022; 14():67-88. PubMed ID: 35023971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
    BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts.
    Deng D; Li X; Qi T; Dai Y; Liu N; Li H
    Front Pharmacol; 2023; 14():1187700. PubMed ID: 37214475
    [No Abstract]   [Full Text] [Related]  

  • 32. Identification of a Prognostic Signature Associated With the Homeobox Gene Family for Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Song J; Zhu M; Zhao S; Ma Y; Yang T
    Front Mol Biosci; 2021; 8():688298. PubMed ID: 34368227
    [No Abstract]   [Full Text] [Related]  

  • 33. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer.
    Wu T; Li S; Yu C; Wu Y; Long H
    Sci Rep; 2022 Dec; 12(1):21467. PubMed ID: 36509838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
    Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
    Front Immunol; 2023; 14():955949. PubMed ID: 37006317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revealing prognostic and tumor microenvironment characteristics of cuproptosis in bladder cancer by genomic analysis.
    Zhang S; Yu S; Duan H; Xia W; Wang C; Shen H
    Front Genet; 2022; 13():997573. PubMed ID: 36263417
    [No Abstract]   [Full Text] [Related]  

  • 36. Identification of Potential Biomarkers for Progression and Prognosis of Bladder Cancer by Comprehensive Bioinformatics Analysis.
    Tan Z; Fu S; Feng R; Huang Y; Li N; Wang H; Wang J
    J Oncol; 2022; 2022():1802706. PubMed ID: 35498536
    [No Abstract]   [Full Text] [Related]  

  • 37. Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
    Caramelo B; Zagorac S; Corral S; Marqués M; Real FX
    Eur Urol Oncol; 2023 Aug; 6(4):366-375. PubMed ID: 36890105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
    Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
    Front Immunol; 2022; 13():964393. PubMed ID: 36211344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia is correlated with the tumor immune microenvironment: Potential application of immunotherapy in bladder cancer.
    Chen H; Zhang Y; Chen X; Xu R; Zhu Y; He D; Cheng Y; Wang Z; Qing X; Cao K
    Cancer Med; 2023 Dec; 12(24):22333-22353. PubMed ID: 38063246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer.
    Song Q; Zhou Z; Bai J; Liu N
    Clin Transl Oncol; 2023 Aug; 25(8):2587-2606. PubMed ID: 37000291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.